Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

By Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino, C. Granger, N. Jones, Lawrence A Leiter, A. Rosenberg, K. Sigmon, M. Somerville and 787 more. The Lancet, 2018

1,439 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/95617ae716e49f4465e6cf72c984001a064e14f5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. J. Meier
2. M. Nauck

Citations in the corpus

• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “While significant reductions in achieving renal composite outcomes were reported [99,164,165], they heavily relied on dominating effects preventing new-onset persistent macroalbuminuria.”
• Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers (2019, background): “A wide range of activities, including yoga, tai chi, and other types, can have significant impacts on A1C, flexibility, muscle strength, and balance (147, 167,168).”
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “468 Speci fi cally, these agents can attenuate the excitability of carotid body cells and diminish sympathetic activation, ultimately leading to a reduction in sympathetic responses.”